Benign Prostatic Hyperplasia Clinical Trials
Here are the 6 most popular medical studies for benign prostatic hyperplasia
Laser Therapy
Thulium Fiber vs MOSES Holmium Laser for Enlarged Prostate
This trial is testing two procedures for benign prostatic hyperplasia (BPH), a non-cancerous enlargement of the prostate. The procedures being tested are transurethral resection of the prostate (TURP) and holmium laser enucleation of the prostate (HoLEP). The study will compare the two procedures in terms of length of hospital stay, intraoperative outcomes, and postoperative outcomes.
Popular filter options for benign prostatic hyperplasia trials
Enlarged Prostate Clinical Trials
View 24 Enlarged Prostate medical studies.
Procedure
Traditional vs Top-Down HoLEP for Enlarged Prostate
This trial will compare the two most common types of surgery for treating an enlarged prostate. HoLEP is a newer, less invasive type of surgery that has a shorter hospital stay, but a longer learning curve for surgeons. The "Top-Down" HoLEP technique is a novel technique which offers potential benefits to the Traditional HoLEP procedure, including decreased complexity, a reduced learning curve.
Beta-3 Adrenoceptor Agonist
Mirabegron +1 More for Overactive Bladder
This trial is testing a new OAB treatment combining a β3-adrenoceptor agonist (mirabegron) with an α-blocker. The goal is to see if this is a safe and effective treatment for OAB symptoms in male patients with BPH.
Thermal Therapy
Prolieve for Enlarged Prostate
The primary objective of the post-marketing study is to collect safety and effectiveness data for 5 years on subjects treated with Prolieve®. The collection of 5-year safety information will be used to evaluate the occurrence of any long-term side effects from the treatment. The collection of long-term effectiveness data on subjects treated with Prolieve® will provide information on the long-term effects of treatment and time to re- treatment (any treatment initiated for BPH since Prolieve'" treatment, including a second treatment with Prolieve").
BPH Clinical Trials
View 10 BPH medical studies.
Arm 1: Preoperative and postoperative pelvic floor physical therapy for Stress Incontinence
This trial is looking at a surgical procedure called Holmium laser enucleation of the prostate (HoLEP) that is used to treat an enlarged prostate. The procedure involves removing part of the prostate
Benign Prostatic Hyperplasia Clinical Trials With No Placebo
View 33 benign prostatic hyperplasia medical studies that do not have a placebo group.
Arm 1: Preoperative and postoperative pelvic floor physical therapy for Stress Incontinence
This trial is looking at a surgical procedure called Holmium laser enucleation of the prostate (HoLEP) that is used to treat an enlarged prostate. The procedure involves removing part of the prostate
Procedure
Traditional vs Top-Down HoLEP for Enlarged Prostate
This trial will compare the two most common types of surgery for treating an enlarged prostate. HoLEP is a newer, less invasive type of surgery that has a shorter hospital stay, but a longer learning curve for surgeons. The "Top-Down" HoLEP technique is a novel technique which offers potential benefits to the Traditional HoLEP procedure, including decreased complexity, a reduced learning curve.
View More Benign Prostatic Hyperplasia Trials
See another 15 medical studies focused on benign prostatic hyperplasia.
Frequently Asked Questions
Introduction to benign prostatic hyperplasia
What are the top hospitals conducting benign prostatic hyperplasia research?
When it comes to cutting-edge clinical trials addressing benign prostatic hyperplasia (BPH), hospitals across the United States are making notable contributions. In Cleveland, Ohio, University Hospitals Cleveland Medical Center takes the lead with one active BPH trial and an equally impressive history of conducting a single trial for this condition thus far. This medical center has demonstrated its commitment to advancing research in BPH since recording its first trial in 2023. Similarly, UH Brainard Medical Bldg in Lyndhurst and UH Regional Hospitals - Richmond Campus in Richmond Heights have also embarked on their own respective active BPH trials and hold a record of one completed trial each—both initiated in 2023.
Moving northward to Thunder Bay Regional Health Sciences Centre situated in Thunder Bay, Canada, we find another medical facility dedicated to exploring solutions for individuals affected by BPH. With one ongoing clinical trial focused on this condition and having commenced their inaugural investigation back in 2022, this center is actively contributing to expanding our understanding of potential treatments for the condition.
Finally, located southwards all away down into Hialeah is Urology Specialist Group where they too are pioneering similar efforts towards finding resolutions tending only one current clinical experiment alongside having successfully conducted singular such investigations since way back as 2020.
These hospitals represent beacons of hope for those suffering from BPH while exemplifying dedication towards advancements within urological health care. Although there may appear few active trials presently underway across these institutions collectively, it's essential to acknowledge that every initiative contributes substantially toward enhanced patient outcomes and better quality of life moving forward
Which are the best cities for benign prostatic hyperplasia clinical trials?
For benign prostatic hyperplasia clinical trials, several cities have emerged as leaders in research and development. Thunder Bay, Ontario takes the lead with 2 active trials investigating treatments such as Thulium Fibre Laser and Top-Down HoLEP. Following closely behind is Cleveland, Ohio, along with its neighboring cities Lyndhurst and Richmond Heights, each hosting 1 active trial focused on Intravesical Botox injection among other interventions. Additionally, Hialeah, Florida joins the ranks with 1 ongoing trial exploring SoracteLite(TM) TPLA for BPH. These cities offer individuals affected by benign prostatic hyperplasia opportunities to participate in cutting-edge clinical trials that strive for improved treatment options and better quality of life.
Which are the top treatments for benign prostatic hyperplasia being explored in clinical trials?
Clinical trials exploring potential treatments for benign prostatic hyperplasia (BPH) have brought several promising options to the forefront. Prostate Artery Embolization, a procedure designed to shrink the prostate gland by blocking its blood supply, is currently being tested in two active trials and has been involved in five all-time BPH trials since its introduction in 2014. Intravesical Botox injection, a minimally invasive treatment that involves injecting botulinum toxin directly into the bladder wall, shows promise with one active trial and one all-time trial dedicated to BPH research since its first listing in 2023. Thulium Fibre Laser therapy and SoracteLite(TM) TPLA are also undergoing investigation through clinical trials for their efficacy against BPH, each with one active trial and one all-time study focused on this condition. As these studies progress, they provide hope for improved management of benign prostatic hyperplasia.
What are the most recent clinical trials for benign prostatic hyperplasia?
Recent clinical trials offer promising advancements in the treatment of benign prostatic hyperplasia (BPH). A Phase 4 trial explores a new treatment group specifically tailored for BPH, potentially providing improved outcomes for patients. Additionally, SoracteLite(TM) TPLA is being investigated in a Phase 1 study as a potential therapeutic option for BPH. These innovative trials aim to address the challenges associated with this condition and enhance patient care.
What benign prostatic hyperplasia clinical trials were recently completed?
Recently completed clinical trials for benign prostatic hyperplasia have provided valuable insights into potential treatment options. In September 2019, Urovant Sciences GmbH successfully concluded a trial investigating the efficacy of Vibegron in addressing this condition. Similarly, another trial sponsored by Urovant Sciences GmbH reached completion in March 2019 and also focused on evaluating the effects of Vibegron. These important studies shed light on the ongoing efforts to find innovative therapeutic approaches for individuals with benign prostatic hyperplasia.